Bipolar Hormone Therapy, BAT for Prostate Cancer, BAT Patient Guide
Cancer ABCs
Bipolar Androgen Therapy (BAT): A Patient's ...

This complete guide to Bipolar Androgen Therapy (BAT) should be your stepping-off point if you are interested in using BAT to treat your castrate-resistant prostate cancer (CrPC).

Bipolar Androgen Therapy (BAT): A Patient's Guide
Radiopharmaceutical Treat
Cancer ABCs
Which is Better, 177Lu-PSMA-617 (Pluvicto) or ...

Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) or Xofigo, a radiopharmaceutical drug that treats bone metastases. There is no simple answer, and the answer is not the same for each of us. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment.

Which is Better, 177Lu-PSMA-617 (Pluvicto) or Xofigo (Radium-223)
PARP Inhibitors, Companion Diagnostics, BRACA
Cancer ABCs
Understanding the PARP Inhibitors - Who Will ...

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with castrate resistant prostate cancer who also have certain genetic mutations. The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes decision making confusing.

Understanding the PARP Inhibitors - Who Will Benefit?
Radiation Side Effect Man, Managing Radiation Side
Cancer ABCs
Managing Late Stage Radiation Side Effects

There are several possible side effects that can result from receiving radiation treatment. The most common of these side effects include the development of scar tissue that makes it hard to urinate (pee), defecate (poop), and in some instances, link the activity of either peeing and pooping together; bladder or colon bleeding and diarrhea. 

Managing Late Stage Radiation Side Effects

68Ga-PSMA

, , ,

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer Recurrence: A Meta-Analysis - Positive Notes

, , ,
Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer Recurrence: A Meta-Analysis - Positive Notes

A meta-analysis was performed to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in men with oligometastatic prostate cancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) (how much radiation to use) and local control (LC) (the success of the radiation treatment in controlling the existing metastases as well as the development of new local metastases).  

, ,

Assessing the Under-Estimation of Nodal Tumor Burden by using 68GA PSMA and 11C-Choline PET/CT Scan

, ,

The technology, PET/CT exemplifies one of the most sensitive of the diagnostic modalities we have to assess the spread of recurrent prostate cancer. 

However, there is an assumption that even PET/CT, despite its sensitivity, still under-estimates the actual tumor burden. There is an additional hypothesis that the under estimation of tumor burden increases progressively by the number of positive nodes that are visualized by preoperative imaging.

Gold Guidestar Seal
Gold Transparency 2022